脂微球前列腺素E_1对2型糖尿病肾病血清TNF-α和CPR的影响  

Effect of lipo-prostaglandin E1 parenteral solution on TNF-α and CRP in patients with type 2 diabetic nephropathy

作　　者：王振华[1] 

机构地区：[1]桓台县人民医院内一科,256400

出　　处：《滨州医学院学报》2010年第4期279-281,共3页Journal of Binzhou Medical University

摘　　要：目的观察脂微球前列腺素E1(Lipo-PGE1)对2型糖尿病肾病患者血清炎性因子的影响,探讨脂微球前列腺素E1治疗2型糖尿病肾病的机制。方法 2型糖尿病肾病患者60例随机分为治疗组和对照组。采用常规降糖、控制血压,稳定2周后,对照组采用丹参治疗2周,治疗组采用Lipo-PGE110μg加入生理盐水20 ml,静脉10 min推入,每日1次。治疗前后检测患者空腹血糖(FBG)、糖化血红蛋白(HbA1c)、尿素氮(BUN)、血肌酐(Scr)、24 h尿白蛋白定量(Uab)、血清中肿瘤坏死因子-α(TNF-α)和C-反应蛋白(CRP)。结果治疗后治疗组血TNF-α、CRP、Uab、Scr、BUN较对照组明显下降,差异有极显著性(P<0.01)。结论 Lipo-PGE1对2型糖尿病肾病患者有显著降低血清TNF-α、CRP的作用;可显著降低2型糖尿病肾病患者尿白蛋白的排泄,有效改善肾功能。Objective To observe the effect of Lipo-PGE1 parenteral solution on hemal cytokines in patients with type 2 diabetic nephropathy and study the curing mechanism of Lipo-PGE1 parenteral solution to diabetic nephropathy.Methods Totally 60 patients with type 2 diabetic nephropathy were randomly divided into treatment group and control group.We used the conventional way to fall the sugar and control blood pressure.Stable 2 weeks later,The control group was treated with Danshen injection intravenously.The treatment group was treated with Lipo-PGE1 10 μg in NS 20 ml intravenously one time every day.Each course lasted for two weeks.The changes of in the patient blood the inflammatory factor tumor necrosis factor-alpha（TNF-α）,C-reactive protein（CRP）,serum creatinine（Scr）,blood urea nitrogen（BUN）,the 24 h urine albumin and fasting plasma glucose（FBG）were observed and recorded.Results After the treatment,the level of TNF-α,CRP,24 h urine albumin,Scr and BUN in treating group was significantly reduced as compared with the control group（P〈0.01）.Conclusion Lipo-PGE1 can obviously reduce the level of blood serum TNF-α,CPR in the type 2 diabetic nephropathy patients,which may be related with its actions in inhibiting the production of inflammatory cytokines.Lipo-PGE1 can obviously decrease urine albumin and improve renal function.

关 键 词：脂微球前列腺素E1 糖尿病肾病 肿瘤坏死因子-α C-反应蛋白 

分 类 号：R587.1[医药卫生—内分泌]